I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademerk Office on September 14, 2007.

Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Examining Group 1609 Patent Application Docket No. INN-123 Serial No. 10/537,394

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Michael J. Teale

Art Unit

1609

Applicants

François Romagne, Hélenè Sicard, Jérôme Tiollier, Christian Belmant

Serial No.

10/537,394

Filed

June 2, 2005

Conf. No.

8478

For

Compositions and Methods for Regulating an Immune Response in a Subject

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik

A Professional Association

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copies of cited references

Substitute for form 1449A/PTO				Complete if Known			
			_	Application Number	10/537,394		
INFORMA				Filing Date	June 2, 2005		
STATEMENT BY APPLICANT				First Named Inventor François Romagne			
(use as many sheets as necessary)				Art Unit	1609		
				Examiner Name	Michael J. Teale		
Sheet	1	of	2	Attorney Docket Number	INN-123		

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	U1	US-7,109,183	09-19-2006	Belmant <i>et al</i> .	All	
	U2	US-7,101,711	09-05-2006	Belmant <i>et al</i> .	All	
	U3	US-2006-0030546-A1	02-09-2006	Jomaa <i>et al.</i>	All	
	U4	US-2005-0042751-A1	02-24-2005	Goldman <i>et al</i> .	All	
	U5	US-2005-0196385-A1	09-08-2005	Romagne <i>et al.</i>	All	
	U6	US-2006-0287281-A1	12-21-2006	Belmant <i>et al.</i>	All	
	U7	US-2006-0287274-A1	12-21-2006	Belmant <i>et al.</i>	All	
	U8	US-2007-0134273-A1	06-14-2007	Romagne <i>et al.</i>	All	
	U9	US-				

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	, i
Examiner Initials*	Cite No. ^t	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

1	Examiner	(Manage Considerate)	Date	04/15/2008
i	Signature	/iviarcos Sznaioman/	Considered	04/10/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/537,394 INFORMATION DISCLOSURE **Filing Date** June 2, 2005 STATEMENT BY APPLICANT First Named Inventor Francois Romagne **Group Art Unit** 1609 (use as many sheets as necessary) Michael J. Teale **Examiner Name**

Sheet

of

2

Attorney Docket Number

INN-123

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VIEY, E. et al. "Peripheral $\gamma\delta$ T-lymphocytes as an innovative tool in	
	R1	immunotherapy for metastic renal cell carcinoma" <i>Expert Rev. Anticancer Ther.</i> , 2005, pp. 1-14, Vol. 5, No. 6.	
		VIEY, E. et al. "Phosphostim-Activated γδ T Cells Kill Autologous Metastatic	
	R2	Renal Cell Carcinoma" <i>The Journal of Immunology</i> , 2005, pp. 1338-1347, Vol. 174.	
	R3	BORDIGNON, C. <i>et al.</i> "Cell therapy: achievements and perspectives" <i>Haematologica</i> , 1999, pp. 1110-1149, Vol. 84.	
		POCCIA, F. <i>et al.</i> "CD94/NKG2 Inhibitory Receptor Complex Modulates Both Anti-Viral and Anti-Tumoral Responses of Polyclonal Phosphoantigen- Reactive Vγ9Vδ2 T Lymphocytes" <i>J. Immunol.</i> , 1997, pp. 6009-6017, Vol.	
	R4	159.	-
	R5	SCIAMMAS, R. <i>et al.</i> "TCR γδ cells and viruses" <i>Microbes and Infection</i> , 1999, pp. 203-212, Vol. 1.	
	R6	KUNZMANN, Volker et al. "Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma" <i>Blood</i> , 2000, pp. 384-392, Vol. 96, No. 2.	
	R7		
	R8		╁
	R9		
	R10		╁
	R11		

Examiner	/Marcos Sznaidman/	Date	04/15/2008
Signature	/Marcos Oznakinan/	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete him. form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.